Developer docs
API playgroundTry for free, no card

Search company profiles

Okeiro

Full company profile

uuid0000raf

Namestring
Okeiro
Legal namestring
Predict4Health
Websiteurl
okeiro.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Okeiro (legally Predict4Health SAS) is a Paris-based precision medicine company developing an AI-driven platform for transplantation and chronic disease management. Its core technology is the iBox algorithm, a multimodal predictive model that estimates individual risk of kidney allograft loss up to 10 years post-evaluation by integrating time from transplant, eGFR, proteinuria/creatininuria ratio, donor-specific antibodies, and biopsy findings. The iBox algorithm holds a C-statistic of 0.81 and has been validated across 7,557 patients in 10 academic centers in Europe and the US, plus a broader network of 44 transplant centers across 5 continents. The platform layers remote patient monitoring, intelligent alerts, predictive scoring, and e-prescribing on top of iBox, and extends into life sciences through sub-products TrialBox (iBox as a qualified surrogate endpoint for clinical trials), Digital Twin (synthetic control arms), and a Real World Evidence System that embeds study protocols into routine clinical workflows.

The company serves three stakeholder groups: healthcare professionals in hospital transplant centers managing kidney, cardiac, liver, and pulmonary insufficiency patients; transplant and chronic disease patients seeking proactive health management; and life sciences companies running clinical trials in transplantation. Its commercial model is enterprise SaaS — annual subscriptions sold through direct field sales to hospitals and pharmaceutical sponsors — with quote-based pricing and a nurse-integration support model for deployment. The company currently counts 500+ healthcare professionals using the platform and has deployed at leading French transplant centers, with stated intent to expand internationally.

Okeiro raised €10M in Series A funding in April 2025 (led by Alven, Forepont Capital Partners, and Red River West) and concurrently rebranded from Predict4Health to Okeiro to signal a broader strategic footprint beyond its founding scope. The funding is earmarked for international expansion and platform development. The company is GDPR-compliant, hosts on Google Cloud, and operates from a single Paris headquarters with approximately 30 dedicated team members.

Short descriptiontext

Okeiro (Predict4Health SAS) is a Paris-based precision medicine company that sells an AI-driven platform for transplant and chronic disease care, anchored by the EMA/FDA-qualified iBox predictive algorithm and used by 500+ healthcare professionals across leading transplant centers in France and globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision medicine platform, transplant predictive analytics, remote patient monitoring, clinical trial surrogate endpoints, real-world evidence system
Industry4 codes
PRIMARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACAFAM
AI/Analytics for RPM (Risk Stratification, Alerts, Predictive)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
NAICS code1 code
  • Home Health Care Services62161
SIC code1 code
  • Services-Health Services8000
Product category
Precision Medicine Software
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Platform Licensing/Subscription
TypeSubscription Recurring
Description

SaaS-based platform subscription model providing access to predictive algorithms, patient monitoring, and clinical trial support tools for healthcare institutions and life sciences companies.

okeiro.com:443
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Enterprise healthcare institution pricing
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based / Not publicly disclosed. Sales via direct contact and demo request process.

okeiro.com:443
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Okeiro offers an AI-driven precision medicine platform for transplantation and chronic disease management, built around its validated iBox algorithm. The platform delivers remote patient monitoring with intelligent alerts and predictive graft-loss scoring, while specialized capabilities support clinical trials via synthetic control arms (Digital Twin) and large-scale real-world evidence generation for transplant and chronic disease cohorts.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • iBox C-statistic: 0.81 (0.79-0.83) for predicting long-term graft outcomes
+3 more records
Product overview1 text field

Okeiro offers a unified precision medicine platform for transplantation and chronic diseases, built around its validated iBox predictive algorithm. The core platform delivers remote patient monitoring with intelligent alerts and predictive scoring, while specialized modules include TrialBox for clinical trial acceleration using iBox as a surrogate endpoint, a Digital Twin for synthetic control arms, and a Real World Evidence System for conducting studies at scale. The platform is designed for three user segments: healthcare professionals requiring patient monitoring tools, patients seeking proactive health management, and life sciences companies conducting clinical research.

Product and service6 records
1iBox Algorithm
CategoryPredictive Analytics
Description

A validated multimodal predictive algorithm that estimates individual risk of kidney allograft loss up to 10 years post-evaluation by integrating eGFR, proteinuria/creatininuria ratio, donor-specific antibodies, and biopsy findings. The first surrogate endpoint for kidney transplant clinical trials with EMA qualification and the first to reach stage 2 of FDA qualification, with a C-statistic of 0.81.

2Okeiro Platform
CategoryClinical Decision Support
Description

A precision medicine platform bridging clinical care and research with validated predictive algorithms, delivering personalized interventions for transplant patients and those with kidney, cardiac, liver, and pulmonary insufficiencies, while accelerating therapeutic innovation through real-world evidence generation.

3TrialBox
CategoryClinical Trial Technology
Description

Clinical trial support system implementing the iBox algorithm as a surrogate endpoint to provide reliable predictions of long-term graft survival, help design more efficient studies, and assess drug efficacy and safety in real-world settings.

4Digital Twin
CategoryClinical Trial Technology
Description

Technology for creating synthetic control arms for clinical trials by generating matched control cohorts that mirror intervention group characteristics, reducing the need for prospective control groups and enabling trials in rare conditions.

5Real World Evidence System
CategoryReal-World Evidence
Description

Platform capability for conducting real-world studies at scale by embedding study protocols into existing clinical care pathways, aggregating clinical documentation, biological, immunological, histological and genetic values, imaging results, medication administration data, and patient-reported outcomes.

6Remote Patient Monitoring
CategoryRemote Patient Monitoring
Description

Precision remote monitoring service for transplant patients and those with chronic diseases, featuring automatic data centralization, intelligent alerts for early warning signs, predictive graft loss scoring, and nurse integration to support healthcare providers.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

French AI-for-healthcare company combining multimodal patient data with proprietary models to support clinical research and drug development. Highly comparable on origin (France), AI-driven multimodal approach, and pharma/biopharma customer base.

2Tempus Labs
TypeBroad incumbent
Description

U.S.-based precision medicine platform combining clinical, molecular, and imaging data to support treatment selection and clinical research. Operates at much larger scale but competes for the same multimodal data + clinical trial acceleration use case Okeiro addresses.

TypeBroad incumbent
Description

Real-world evidence platform focused on oncology, aggregating EMR and clinical data for pharma-sponsored research. Comparable in the real-world evidence and clinical trial surrogate endpoint value proposition, though focused on oncology rather than transplantation.

TypeDirect peer
Description

Real-world evidence company that curates specialty disease databases (ophthalmology, neurology, urology) for clinical research and pharma decision-making. Closely aligned in building disease-specific evidence networks that pharma sponsors use to accelerate trials.

TypeBroad incumbent
Description

Healthcare analytics platform providing real-world patient journey insights to life sciences companies. Comparable in the life-sciences-facing analytics and real-world evidence layer, though broader in therapeutic scope than Okeiro.

TypeBroad incumbent
Description

Clinical trial technology platform offering EDC, eCOA, and trial design tools to pharma sponsors. Most directly comparable in the clinical trial surrogate endpoint / TrialBox product layer, and the parent (Dassault Systèmes) is also headquartered in France.

TypeBroad incumbent
Description

Global leader in clinical research services, real-world evidence, and healthcare data analytics. Competes for the same pharma RWE and clinical trial acceleration budgets Okeiro targets via TrialBox and the Digital Twin.

8Caresyntax
TypeDirect peer
Description

AI-driven surgical and clinical analytics platform aggregating intraoperative and outcomes data to support hospital performance and clinical research. Comparable as a multimodal clinical AI platform selling into hospitals and life sciences.

TypeDirect peer
Description

French digital therapeutics company building SaMD platforms for chronic disease management and patient monitoring. Comparable as a French-origin digital health platform pairing patient monitoring with clinical research-grade data.

TypeEmerging player
Description

French AI platform for cardiac diagnostics (now part of Philips), illustrating another French health AI success in a single therapeutic area. Comparable on the French origin and clinical AI specialisation, but a different organ and use case (diagnostics vs. transplant care).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Okeiro

Precision Medicine Softwareokeiro.com

Okeiro (Predict4Health SAS) is a Paris-based precision medicine company that sells an AI-driven platform for transplant and chronic disease care, anchored by the EMA/FDA-qualified iBox predictive algorithm and used by 500+ healthcare professionals across leading transplant centers in France and globally.

What Okeiro does

Okeiro (legally Predict4Health SAS) is a Paris-based precision medicine company developing an AI-driven platform for transplantation and chronic disease management. Its core technology is the iBox algorithm, a multimodal predictive model that estimates individual risk of kidney allograft loss up to 10 years post-evaluation by integrating time from transplant, eGFR, proteinuria/creatininuria ratio, donor-specific antibodies, and biopsy findings. The iBox algorithm holds a C-statistic of 0.81 and has been validated across 7,557 patients in 10 academic centers in Europe and the US, plus a broader network of 44 transplant centers across 5 continents. The platform layers remote patient monitoring, intelligent alerts, predictive scoring, and e-prescribing on top of iBox, and extends into life sciences through sub-products TrialBox (iBox as a qualified surrogate endpoint for clinical trials), Digital Twin (synthetic control arms), and a Real World Evidence System that embeds study protocols into routine clinical workflows.

The company serves three stakeholder groups: healthcare professionals in hospital transplant centers managing kidney, cardiac, liver, and pulmonary insufficiency patients; transplant and chronic disease patients seeking proactive health management; and life sciences companies running clinical trials in transplantation. Its commercial model is enterprise SaaS — annual subscriptions sold through direct field sales to hospitals and pharmaceutical sponsors — with quote-based pricing and a nurse-integration support model for deployment. The company currently counts 500+ healthcare professionals using the platform and has deployed at leading French transplant centers, with stated intent to expand internationally.

Okeiro raised €10M in Series A funding in April 2025 (led by Alven, Forepont Capital Partners, and Red River West) and concurrently rebranded from Predict4Health to Okeiro to signal a broader strategic footprint beyond its founding scope. The funding is earmarked for international expansion and platform development. The company is GDPR-compliant, hosts on Google Cloud, and operates from a single Paris headquarters with approximately 30 dedicated team members.

Okeiro firmographics

Firmographics
Name
Okeiro
Legal name
Predict4Health
Website
https://okeiro.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
Okeiro (Predict4Health SAS) is a Paris-based precision medicine company that sells an AI-driven platform for transplant and chronic disease care, anchored by the EMA/FDA-qualified iBox predictive algorithm and used by 500+ healthcare professionals across leading transplant centers in France and globally.
Ownership category
akta.pro rank

Okeiro industry classification

Industry
Product category
Precision Medicine Software
NAICS
Home Health Care Services (62161)
SIC
Services-Health Services (8000)
akta.pro industry
PRIMARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACAFAM
AI/Analytics for RPM (Risk Stratification, Alerts, Predictive)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

Keywords

  • Precision medicine platform
  • Transplant predictive analytics
  • Remote patient monitoring
  • Clinical trial surrogate endpoints
  • Real-world evidence system

Where Okeiro is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Okeiro business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Platform Licensing/Subscription: SaaS-based platform subscription model providing access to predictive algorithms, patient monitoring, and clinical trial support tools for healthcare institutions and life sciences companies.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise healthcare institution pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Okeiro product offering

Product offering

Core offering

Okeiro offers an AI-driven precision medicine platform for transplantation and chronic disease management, built around its validated iBox algorithm. The platform delivers remote patient monitoring with intelligent alerts and predictive graft-loss scoring, while specialized capabilities support clinical trials via synthetic control arms (Digital Twin) and large-scale real-world evidence generation for transplant and chronic disease cohorts.

Product overview

Okeiro offers a unified precision medicine platform for transplantation and chronic diseases, built around its validated iBox predictive algorithm. The core platform delivers remote patient monitoring with intelligent alerts and predictive scoring, while specialized modules include TrialBox for clinical trial acceleration using iBox as a surrogate endpoint, a Digital Twin for synthetic control arms, and a Real World Evidence System for conducting studies at scale. The platform is designed for three user segments: healthcare professionals requiring patient monitoring tools, patients seeking proactive health management, and life sciences companies conducting clinical research.

Differentiator

Problem solved

Functional benefit

Products and services

  • iBox Algorithm A validated multimodal predictive algorithm that estimates individual risk of kidney allograft loss up to 10 years post-evaluation by integrating eGFR, proteinuria/creatininuria ratio, donor-specific antibodies, and biopsy findings. The first surrogate endpoint for kidney transplant clinical trials with EMA qualification and the first to reach stage 2 of FDA qualification, with a C-statistic of 0.81.
  • Okeiro Platform A precision medicine platform bridging clinical care and research with validated predictive algorithms, delivering personalized interventions for transplant patients and those with kidney, cardiac, liver, and pulmonary insufficiencies, while accelerating therapeutic innovation through real-world evidence generation.
  • TrialBox Clinical trial support system implementing the iBox algorithm as a surrogate endpoint to provide reliable predictions of long-term graft survival, help design more efficient studies, and assess drug efficacy and safety in real-world settings.
  • Digital Twin Technology for creating synthetic control arms for clinical trials by generating matched control cohorts that mirror intervention group characteristics, reducing the need for prospective control groups and enabling trials in rare conditions.
  • Real World Evidence System Platform capability for conducting real-world studies at scale by embedding study protocols into existing clinical care pathways, aggregating clinical documentation, biological, immunological, histological and genetic values, imaging results, medication administration data, and patient-reported outcomes.
  • Remote Patient Monitoring Precision remote monitoring service for transplant patients and those with chronic diseases, featuring automatic data centralization, intelligent alerts for early warning signs, predictive graft loss scoring, and nurse integration to support healthcare providers.

Quantifiable outcome

  • iBox C-statistic: 0.81 (0.79-0.83) for predicting long-term graft outcomes
  • +3 more outcomes

Companies that use Okeiro

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Okeiro technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

Okeiro partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Okeiro competitors and assessment

Company assessment

Direct peers

  • Owkin: French AI-for-healthcare company combining multimodal patient data with proprietary models to support clinical research and drug development. Highly comparable on origin (France), AI-driven multimodal approach, and pharma/biopharma customer base.
  • Verana Health: Real-world evidence company that curates specialty disease databases (ophthalmology, neurology, urology) for clinical research and pharma decision-making. Closely aligned in building disease-specific evidence networks that pharma sponsors use to accelerate trials.
  • Caresyntax: AI-driven surgical and clinical analytics platform aggregating intraoperative and outcomes data to support hospital performance and clinical research. Comparable as a multimodal clinical AI platform selling into hospitals and life sciences.
  • Voluntis: French digital therapeutics company building SaMD platforms for chronic disease management and patient monitoring. Comparable as a French-origin digital health platform pairing patient monitoring with clinical research-grade data.

Broad incumbents

  • Tempus Labs: U.S.-based precision medicine platform combining clinical, molecular, and imaging data to support treatment selection and clinical research. Operates at much larger scale but competes for the same multimodal data + clinical trial acceleration use case Okeiro addresses.
  • Flatiron Health: Real-world evidence platform focused on oncology, aggregating EMR and clinical data for pharma-sponsored research. Comparable in the real-world evidence and clinical trial surrogate endpoint value proposition, though focused on oncology rather than transplantation.
  • Komodo Health: Healthcare analytics platform providing real-world patient journey insights to life sciences companies. Comparable in the life-sciences-facing analytics and real-world evidence layer, though broader in therapeutic scope than Okeiro.
  • Medidata Solutions (Dassault Systèmes): Clinical trial technology platform offering EDC, eCOA, and trial design tools to pharma sponsors. Most directly comparable in the clinical trial surrogate endpoint / TrialBox product layer, and the parent (Dassault Systèmes) is also headquartered in France.
  • IQVIA: Global leader in clinical research services, real-world evidence, and healthcare data analytics. Competes for the same pharma RWE and clinical trial acceleration budgets Okeiro targets via TrialBox and the Digital Twin.

Emerging players

  • Cardiologs: French AI platform for cardiac diagnostics (now part of Philips), illustrating another French health AI success in a single therapeutic area. Comparable on the French origin and clinical AI specialisation, but a different organ and use case (diagnostics vs. transplant care).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Okeiro compliance and trust

Trust signal

Compliance1 record

Okeiro financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Okeiro leadership team

Management profile

Number of profiles

Profiles1 record

Okeiro funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Okeiro M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Okeiro

What does Okeiro do?

Okeiro offers an AI-driven precision medicine platform for transplantation and chronic disease management, built around its validated iBox algorithm. The platform delivers remote patient monitoring with intelligent alerts and predictive graft-loss scoring, while specialized capabilities support clinical trials via synthetic control arms (Digital Twin) and large-scale real-world evidence generation for transplant and chronic disease cohorts.

Is Okeiro a public or private company?

Okeiro is a private company. It is classified as venture growth investor backed and is currently operating.

When was Okeiro founded?

Okeiro was founded in 2023. It employs 11 to 50 people.

Where is Okeiro based?

Okeiro is headquartered in Paris, France, in the Europe region.

How does Okeiro make money?

One revenue line is on record: platform Licensing/Subscription.

Who are Okeiro's main competitors?

Direct peers on record are Owkin, Verana Health, Caresyntax and Voluntis. Broad incumbents are Tempus Labs, Flatiron Health, Komodo Health, Medidata Solutions (Dassault Systèmes) and IQVIA. Cardiologs is listed as an emerging player.

Does Okeiro have an API?

No public API is recorded for Okeiro.

What industry is Okeiro in?

Okeiro's product category is Precision Medicine Software. Its primary akta.pro industry code is HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints, with a secondary code of HLACAFAM, AI/Analytics for RPM (Risk Stratification, Alerts, Predictive). Its NAICS code is 62161 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireAI Disrupts HLA Typing for Transplantation: Investment Activity Accelerates as Genomic Matching Enters a New EraBCC Research released a Pulse Report on artificial intelligence's impact on human leukocyte antigen typing for transplant medicine, covering donor-recipient matching, registry operations, and clinical decision platforms. The report finds North America leads AI adoption, while Asia-Pacific, the Middle East and South America expand donor registries, and cites eGenesis, SeqOne, Okeiro and InformAI among investors. It flags GDPR, the EU AI Act, algorithmic bias and uneven digital infrastructure as risks.FinSMEsOkeiro Raises €10M in FundingOkeiro, a Paris-based precision medicine company, raised €10M in funding led by Alven, Forepont Capital Partners, and Red River West. The funds will accelerate deployment and develop AI tools for diagnostics and clinical research. The company is conducting a randomized clinical trial across 16 hospital centers in six countries.ThetopvoicesOkeiro Raises €10M to Transform Transplant Care with AIOkeiro, a precision medicine company, closed a €10 million funding round led by Alven, Forepont Capital Partners, and Red River West. The funds will support expansion in Europe and prepare for a U.S. market entry later this year. The company's AI platform, iBox, is clinically validated and integrated into French transplant centers.GlobeNewswireOkeiro raises €10 Million to accelerate development of its Precision Medicine platform for Transplantation and Chronic DiseasesOkeiro raised €10 million in a funding round led by Alven, Forepont Capital Partners, and Red River West to accelerate its precision medicine platform for transplantation and chronic diseases. The platform's iBox algorithm is a clinically validated predictive model qualified as a surrogate endpoint by FDA and EMA. The company plans to expand across Europe and enter the US market this year.GlobeNewswireOkeiro raises €10 Million to accelerate development of its Precision Medicine platform for Transplantation and Chronic DiseasesOkeiro raised €10 million in a funding round led by Alven, Forepont Capital Partners, and Red River West to accelerate its precision medicine platform for transplantation and chronic diseases. The platform's iBox algorithm is FDA and EMA-qualified as a surrogate endpoint, and the company plans US market entry this year.